Haleon (HLN) Net Margin (2021 - 2025)

Haleon's (HLN) quarterly Net Margin came in at 14.71% in Q4 2025, up 82.75% on a QoQ basis from 8.05% in Q4 2023.

Haleon (HLN) Net Margin (2021 - 2025) Analysis & Trends

Haleon (HLN) has 4 years of Net Margin data on file, last reported at 14.71% in Q4 2025.

Quarterly Net Margin changed N/A year-over-year to 14.71% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 7.72% (changed N/A YoY) and the FY2025 annual result came in at 15.11%, up 228.0% from the prior year.
Net Margin improved to 14.71% in Q4 2025, from 8.05% in the prior quarter.
In the past five years, Net Margin ranged from a high of 32.81% in Q4 2022 to a low of 8.05% in Q4 2023.
A 4-year average of 15.27% and a median of 12.61% in 2023 frame the typical range for Net Margin.
Annual changes were most pronounced in 2022 — Net Margin soared 2061 bps — and 2023, when it slumped 2476 bps.
Tracing HLN's Net Margin over 4 years: stood at 12.2% in 2021, then surged by 169 bps to 32.81% in 2022, then sank by 75 bps to 8.05% in 2023, then surged by 83 bps to 14.71% in 2025.
The last three Net Margin figures came in at 14.71% (Q4 2025), 8.05% (Q4 2023), and 10.83% (Q2 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Haleon	43.65 Bn	42.68 Bn	-	-
2	Teva Pharmaceutical Industries	43.09 Bn	39.44 Bn	2.15 Bn	-13.91%
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	35.09%
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	9.28%
5	United Therapeutics	22.11 Bn	19.45 Bn	683.80 Mn	42.51%
6	Viatris	18.77 Bn	17.88 Bn	1.46 Bn	-3.16%
7	Neurocrine Biosciences	15.62 Bn	15.23 Bn	935.80 Mn	15.06%
8	Elanco Animal Health	12.07 Bn	11.54 Bn	798.00 Mn	3.95%
9	Dr Reddys Laboratories	10.09 Bn	9.93 Bn	-	-
10	Alkermes	8.20 Bn	7.54 Bn	397.90 Mn	0.11%

Download Data